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ABSTRACT 
 
Background 
Cystic fibrosis (CF) is one of the most common fatal autosomal recessive inherited 
conditions in the Caucasian population.   Survival of patients with cystic fibrosis has 
increased due to optimal medical therapy and as a consequence, later complications such 
as cystic fibrosis related diabetes (CFRD) may develop.  
 
Materials and methods 
A retrospective patient file review was conducted on all the patient files in the Adult 
Cystic Fibrosis Unit, Ward 496, Charlotte Maxeke Johannesburg Academic Hospital. 
The aim of the review was to determine the prevalence of Cystic fibrosis related diabetes 
(CFRD) and to determine the characteristics of patients with CFRD in terms of age, 
gender, genotype, lung function, body mass index (BMI), HBA1c, use of corticosteroids 
and pancreatic function.   
 
Patients were classified as normal glucose tolerance, impaired glucose tolerance or CFRD 
based on the results of oral glucose tolerance testing.  For statistical analysis, patients 
with impaired glucose tolerance and CFRD were analyzed together under the group 
abnormal glucose homeostasis. 
 
50 patient files were reviewed.  
 
Results 
12 patients (24%) had normal glucose tolerance, 10 (20%) had impaired glucose 
tolerance, 23 (46%) had CFRD without fasting hyperglycaemia and 3 patients (6%) had 
CFRD with fasting hyperglycaemia. 2 patients (4%) did not have OGTT done and 
therefore could not be categorised.  The prevalence of CFRD was 54 % (including all 
patients with CFRD without fasting hyperglycaemia and patients with CFRD with fasting 
hyperglycaemia).  75 % of patients had abnormal glucose homeostasis.  Statistical 
analysis failed to demonstrate any significant difference in the characteristics of patients 
with and without CFRD.  This may be related to the small sample size.  HBA1c values 
were higher in patients with abnormal glucose homeostasis compared to patients with 
normal glucose tolerance. 
 
Conclusions 
The prevalence of CFRD in the adult cystic fibrosis population at Charlotte Maxeke 
Johannesburg Academic Hospital correlates with the prevalence of CFRD in other cystic 
fibrosis centres.  There were no statistically significant differences in the characteristics 
of patients with and without CFRD. 
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1.0 INTRODUCTION 
This research report involved a retrospective patient file review on all the patient files 
in the adult cystic fibrosis (CF) unit, Ward 496, Charlotte Maxeke Johannesburg 
Academic Hospital. The research report fulfils part of the requirements for the degree 
of Master of Medicine in the branch of Internal Medicine.   
 
The patient population under review included all the patients attending the cystic 
fibrosis clinic from 2004 till November 2009.  The aim of the research report is to 
determine the prevalence of CFRD in this population of CF patients and to determine 
the characteristics of the patients with CFRD in terms of age, gender, genotype, lung 
function, body mass index (BMI), HBA1c, use of corticosteroids and pancreatic 
function.  There is currently no data available in South Africa regarding these 
statistics.  
 
The research report will begin with a literature review focusing on cystic fibrosis and 
specifically cystic fibrosis related diabetes (CFRD).  The epidemiology, pathogenesis, 
complications, diagnosis and management of CFRD will be discussed.  The methods 
used in the research report including details of the statistical analyses will be 
mentioned.  The results of the retrospective review will be presented and compared 
with data from other cystic fibrosis centres.   
 
1.1 Literature review 
 
Cystic fibrosis is one of the most common fatal autosomal recessive inherited 
conditions in the Caucasian population with an incidence of 1 per 2500 live births.  
The genetic defect involves the long arm of Chromosome 7 and results in abnormal 
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synthesis of the cystic fibrosis transmembrane regulator (CFTR).  This protein is 
responsible for regulation of water and electrolyte composition of bodily fluids and 
defects in the CFTR result in abnormal viscous secretions leading to mucus plugs 
which precipitate pulmonary, pancreatic, gastrointestinal and genitourinary 
complications.  A patient with CF may present with chronic airway infections with 
resultant bronchiectasis, exocrine pancreatic insufficiency, intestinal dysfunction, 
urogenital dysfunction and abnormal sweat gland function. The degree of clinical 
dysfunction depends primarily on which mutations are present in a patient with cystic 
fibrosis.   
 
There are over 1500 known mutations, which are divided into five classes based on 
phenotypic severity of the cystic fibrosis.  Classes I – III are associated with more 
severe clinical symptoms due to major abnormalities in the CFTR channel.  Classes 
IV – V lead to milder forms of disease (Rowe, Miller & Sorscher 2005). 
The most common mutation is the !F508 mutation (loss of a phenylalanine residue at 
position 508).  It is a class II mutation and is identified in 70% of CF patients 
(Preumont, Hermans & Buysschaert 2008).  Patients are classified as homozygous if 
both alleles have the !F508 mutation and heterozygous if only one !F508 mutation is 
present.  
 
Survival rates among cystic fibrosis patients have improved due to optimal medical 
management and the current life expectancy is around 37.4 years according to the CF 
Foundation Registry (Marshall et al. 2009).  As a consequence of improved survival, 
later complications may develop such as cystic fibrosis related diabetes (CFRD) and 
cystic fibrosis related bone disease. 
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1.2 Cystic fibrosis related diabetes 
The American Diabetes Association classifies diabetes into four categories namely, 
Category I (Type 1), Category II (Type 2), Category III (Other specific types) and 
Category IV (Gestational diabetes).  CFRD is classified in the category of ‘Other 
specific types [of diabetes]’ (Category III) under the sub-heading ‘C. Diseases of the 
exocrine pancreas’.  
Other types of diabetes included under this heading refer to diabetes due to 
pancreatitis, trauma, neoplasia and haemochromatosis.   
CFRD shares features of both type 1 and type 2 diabetes.  
 
1.2.1 Epidemiology 
 
CFRD has an average age of onset of 18 – 21 years (Lanng et al. 1994a) with less 
than 10% of cases of occurring before the age of 10 and more than 40% of cases 
occurring in patients older than 30 years (Lanng et al. 1994a, Lanng et al. 1995).   
 
The prevalence of CFRD among European patients with cystic fibrosis approximates 
12 % in children and 30 % in adults with an average age dependent increase of 4-9% 
(Lanng et al. 1995, Adler et al. 2007).  In Denmark, annual oral glucose tolerance 
screening is performed on all CF patients and the prevalence of CFRD is 50 % of the 
CF population older than 30 years of age (Lanng et al. 1994a).  A recent study of the 
Dutch CF population showed the prevalence of CFRD to be 40% overall and this 
figure rose to 52% in patients older than 40 years (van den Berg, Kouwenberg & 
Heijerman 2009). 
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A study performed in 1999 in Italy followed CF patients over a 10 year period and 
showed that 42.8% of patients developed diabetes over the 10 year period (Cucinotta 
et al. 1999).   
The CF patient group receiving treatment at the University of Minnesota in America 
had a prevalence of CFRD of 2% of children, 19% of adolescents and 40-50% of 
adult (Moran et al. 2009). 
 
The risk for developing CFRD is increased with increasing age, presence of exocrine 
pancreatic insufficiency, !F508 homozygous genotype, lower BMI and female gender 
(Marshall et al. 2005, Bismuth et al. 2008, Blackman et al. 2009, van den Berg, 
Kouwenberg & Heijerman 2009).  It is unclear whether the use of corticosteroids is 
associated with an increased incidence of CFRD (Marshall et al. 2005).     
 
 
1.2.2 Pathogenesis  
 
Glucose metabolism is influenced by many factors in patients with Cystic Fibrosis 
including malnutrition, elevated energy expenditure, acute and chronic infections, 
glucagon deficiency, malabsorption, abnormal transit time of glucose in the GUT, 
liver disease and increased work of breathing (Marshall et al. 2005). 
 
Insulin is secreted by the beta (") cells of the pancreatic Islets of Langerhans in 
response to a glucose load in normal healthy individuals.  The release of insulin 
occurs in two phases namely first-phase and second-phase insulin release.   
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First phase insulin release results in a rapid increase in plasma insulin after ingestion 
of a glucose load.  The first phase insulin release prevents postprandial 
hyperglycaemia. Second-phase insulin release follows first-phase insulin release and 
results in slower, sustained release of insulin.  
 
In CFRD patients, there is defective pancreatic " cell function due to progressive 
destruction and fibrosis of the " cells as well as amyloid deposition and fatty 
infiltration of the pancreas. This results in defective first- phase insulin release 
resulting in a delayed peak in insulin secretion which results in postprandial 
hyperglycaemia.  In this way, CFRD shares features of Type 1 diabetes but patients 
with CFRD are not prone to ketoacidosis (Mohan et al. 2009). 
 
Type 2 diabetes is characterized by insulin resistance. The role of insulin resistance in 
the pathogenesis of CFRD remains unclear.  Insulin sensitivity in a patient with CF 
may vary at any given point in time and is affected by the individual’s age, nutritional 
status, degree of underlying pulmonary disease and the presence and severity of 
underlying chronic infections (Lombardo et al. 2003).  A patient may therefore have 
normal, decreased or increased insulin sensitivity.  
 
Patients may therefore experience fluctuations in their degree of glucose intolerance 
depending on their overall health, nutritional status and concurrent medication usage 
(including corticosteroids) (Zirbes, Milla 2009). 
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1.2.3 Complications 
 
CFRD is associated with increased morbidity and results in a six-fold increase in 
mortality (Mohan et al. 2009).   Patients with CFRD are reported to have a median 
survival of 35.6 years compared to non-CFRD patients who have a median survival of 
47.0 years.  Female patients with CFRD have higher mortality rates than male patients 
who appear to have the same mortality as patients without CFRD (Milla, Billings & 
Moran 2005).   
 
Microvascular complications of diabetes namely retinopathy, nephropathy, 
gastropathy and neuropathy occur in patients with CFRD.  The risk of macrovascular 
complications does not appear to be increased (Schwarzenberg et al. 2007). 
 
Patients with CFRD have been reported to have a lower forced expiratory volume in 
one second (FEV1), a more rapid decline in pulmonary function and have more 
frequent  pulmonary exacerbations than patients without CFRD. These findings may 
either indicate that patients with more severe cystic fibrosis may develop CFRD or it 
may indicate that CFRD itself, contributes to disease progression and is not only a 
marker of advanced disease (Lanng et al. 1994b).   
 
CFRD is also associated with greater nutritional compromise that results in stunted 
growth and further deterioration in lung function (Lanng et al. 1994b).  Insulin is an 
anabolic hormone and the relative insulin deficiency may in part explain the 
nutritional compromise (Marshall et al. 2005).   The above factors, namely lower 
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FEV1 and greater nutritional compromise, raise an important question.  Are sicker 
patients more likely to develop CFRD or does the presence of CFRD make patients 
with CF sicker? (Marshall et al. 2005).   
 
Initiation of insulin therapy results in weight gain and an improvement in pulmonary 
function suggesting that insulin deficiency is a direct cause of the declining health 
status (Lanng et al. 1994b). A further study showed that the rate of decline in 
pulmonary function was directly proportional to the degree of glucose intolerance and 
an inverse relationship was demonstrated between the rate of decline in pulmonary 
function and the level of insulin secretion at baseline (Milla, Warwick & Moran 
2000).  This study further supports the fact that insulin deficiency leads to the 
deterioration in health status.   
 
 
1.2.4 Diagnosis and Screening 
 
CFRD should be considered in all CF patients with symptoms of diabetes like 
polyuria and polydipsia, poor weight gain, poor growth velocity and unexplained 
chronic decline in pulmonary function.  The decline in pulmonary function and 
weight may predate the diagnosis of CFRD by about 6 years.   
 
Oral glucose tolerance testing (OGTT) is the recommended screening method for the 
detection CFRD (UK Cystic Fibrosis Trust Working Group 2004).  According to the 
UK CF trust working group, a screening OGTT is suggested for CF patients older 
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than 12 years old.   The American CF consensus guidelines suggest routine OGTT for 
CF patients older than 10 years (Yankaskas et al. 2004). 
 
Three days prior to an OGTT the patient should consume at least 150g/day of 
carbohydrate and then fast overnight prior to the test.  The OGTT is then performed 
by giving an oral glucose load of 1.75g/kg (Maximum 75g) mixed with 300mls of 
water to the patient to be ingested within 5 minutes.  Blood samples are collected 
before the ingestion of the glucose and 2 hours after ingestion.  The OGTT should be 
performed during periods of clinical stability as acute illness and stress may affect 
glucose metabolism. 
 
 
Four categories of glucose tolerance are recognized based on the OGTT (Table 1.1): 
# Normal glucose tolerance (NGT) 
# Impaired glucose tolerance (IGT) 
# CFRD without fasting hyperglycaemia 
# CFRD with fasting hyperglycaemia  
(Moran et al. 1999) 
 
The criteria for the diagnosis of CFRD include: 
# 2 hour plasma glucose (PG) > 11mmol/l during a 75g OGTT 
# Fasting plasma glucose (FPG) > 7mmol/l on two or more occasions 
# FPG > 7mmol plus casual glucose level of > 11.1mmol/l 
# Casual glucose levels > 11.1 on two or more occasions with symptoms  
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Table 1.1: Categories of glucose tolerance in patients with CF based on response 
to oral glucose tolerance testing 
 
 
*Abnormal glucose homeostasis  
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition Fasting plasma glucose 
(mmol/l) 
2 hour plasma glucose 
(mmol/l) 
Normal glucose tolerance (NGT) <7 <7.8 
Impaired glucose tolerance 
(IGT)* 
<7 7.8 – 11.1 
CFRD without fasting 
hyperglycaemia* 
<7 > 11.1 
CFRD with fasting 
hyperglycaemia* 
>7 OGTT not indicated 
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From the table it can be seen that patients with fasting plasma glucose levels > 7 
mmol/l on two or more occasions are classified as having CFRD with fasting 
hyperglycaemia.  A fasting plasma glucose level that is < 7 mmol/l will miss patients 
with CFRD without fasting hyperglycaemia and therefore an OGTT should be 
performed on all patients (Moran et al. 1999). 
 
 
It is also possible to classify patients based on the oral glucose tolerance test into two 
groups, namely normal glucose tolerance and abnormal glucose homeostasis.  The 
latter group includes patients with impaired glucose tolerance, CFRD without fasting 
hyperglycaemia and CFRD with fasting hyperglycaemia (Preumont, Hermans & 
Buysschaert 2008).   
 
Oral glucose tolerance testing, while being the preferred method for screening, has a 
few drawbacks.  The OGTT creates artificial glucose conditions in the patients and 
the current guidelines for interpretation of the test are based on other patients with 
diabetes, not specifically patients with CFRD.  The cut-off points for diabetes 
according to the OGTT are based on data relating to prevention of cardiovascular 
complications.  Patients with CFRD often show a decline in overall health before any 
abnormality will be seen on the OGTT and perhaps lower values should be used in the 
diagnosis of CFRD.  As discussed earlier, glucose homeostasis in the patient with CF 
is affected by many factors and this may play a role in the interpretation of the test.   
For this reason, the test should be performed during periods of clinical stability. 
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Due to the problems associated with the OGTT, continuous glucose monitoring 
(CGM) is another tool that has now been used to assess CFRD.  The test offers a 
broader view of glucose control under real life situations as opposed to the artificial 
conditions created by the OGTT.  Earlier abnormalities in glucose tolerance may be 
detected using CGM.  The test is costly and time consuming and is only being used in 
research studies (Franzese et al. 2008).   
 
Haemoglobin A1c (HBA1c) is used to determine the long term glycaemic control in 
patients with diabetes.  HBA1c should not be used as a screening test for CFRD as the 
values are usually normal in patients with CFRD.  There are numerous reasons for 
this.  In the early phases of CFRD, intermittent hyperglycaemia is present and this 
may not be intense or prolonged enough to raise the HBA1c.  Another theory is that 
red cell survival may be shortened in patients with CF due to the effects of chronic 
inflammation thus leading to spuriously low HBA1c levels (Lanng et al. 1995). 
 
No matter how CFRD has been diagnosed, correct management is vital to limit the 
significant complications associated with the condition. 
 
1.2.5 Management 
Insulin remains the mainstay of treatment for patients with CFRD based on the 
pathophysiology of the disease.   Patients with CFRD with fasting hyperglycaemia 
will definitely require insulin.  Patients with CFRD without fasting hyperglycaemia 
and patients with impaired glucose tolerance may require insulin especially during 
times of stress and illness as well as when taking medications like corticosteroids as 
their glucose homeostasis will change during these times. 
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Oral agents like sulphonylureas and glyburide have been used for patients with CFRD 
without fasting hyperglycaemia in an attempt to improve insulin sensitivity.  There is 
no evidence to suggest that they are of any benefit as the primary problem in CFRD is 
insulin deficiency.  There is a concern about toxicity with oral agents as 
sulphonylureas bind to CFTR and glyburide is eliminated in the bile and toxic levels 
may increase in patients with Cystic Fibrosis (Moran et al. 1999).  
 
The patient with CFRD should be managed in a specialist unit as there are some 
important differences and considerations compared to other patients with type 1 and 
type 2 diabetes.  The dose of insulin will need to be adjusted during stress, illness and 
when taking corticosteroids.  Many patients with CF have increased sputum 
production during the morning and as a result may not eat breakfast.  The dose of 
insulin may therefore need to be decreased in the morning (Alexander, Bridges 2010).  
Some CF patients receive nasogastric feeds at night to supplement their diet and 
insulin requirements may increase at night. 
 
Diet modification is very different when compared to other patients with diabetes.  
Patients with CF are catabolic due to chronic inflammation and will require an 
increased amount of calories.  High glycaemic index foods and beverages should be 
avoided (Alexander, Bridges 2010). 
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2.0 METHODS 
2.1 Study sample 
 
This study involved a retrospective patient file review on all the patient files in the 
Adult Cystic Fibrosis Unit, Ward 496, Charlotte Maxeke Johannesburg Academic 
Hospital.  This included all files currently available from the inception of the clinic in 
2004 till November 2009.  The total number of files reviewed was 50.  The file review 
was conducted from September to November 2009. 
 
The retrospective patient file review was performed after obtaining ethical clearance 
from the Human Research Ethics Committee at the University of the Witwatersrand 
(Reference R14/49, clearance certificate M090905). Written permission to perform 
the study was also obtained from the acting Chief Executive Officer (CEO) of 
Charlotte Maxeke Johannesburg Academic Hospital, Dr S.B. Mfenyana. 
 
2.2 Study information 
The following information was obtained from the patient files: 
# Age at most recent visit (in years) 
# Sex 
# Genotype based on evidence available at the time of record review 
Patients were classified into three groups:  
# Homozygous for !F508 mutation if two !F508 mutations were present 
# Heterozygous for !F508 mutation if only one !F508 mutation was present  
# Other if two other mutations were present 
# Body mass index (BMI) as at most recent visit in kg/m
2
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# Lung function based on the most recent forced expiratory volume in 1 second 
(FEV1) in liters per second and percentage of calculated value. 
# Degree of exocrine pancreatic insufficiency was assessed by the amount of 
pancreatic enzyme replacement required in the (Creon) 
# Corticosteroid usage was determined.  If corticosteroids had been used at any 
point during the patient’s time at the CF clinic (2004 to 2009), the duration, 
cumulative dose and maximum single dose of corticosteroid used were 
documented.  All corticosteroids used were converted to the equivalent dose of 
prednisone.  The total duration of corticosteroid usage over the years that the 
patient attended the CF clinic as well as the maximum single course dosages 
were used in the data analysis. 
# Evidence of CFRD based on the most recent OGTT 
# HbA1c based on the most recent blood tests performed at the CF clinic. 
 
2.3 Statistical analysis  
The information collected from the files was placed onto a data sheet and later 
formulated into an Excel spreadsheet to facilitate data analysis.  The data was 
analyzed using basic statistics on Excel as well as Statistica (Version 8.0, Statsoft, 
USA) for continuous variables.  For categorical variables the statistical program SAS 
(Version 9.2, SAS Institute Inc., USA) was used. 
 
The 50 patients were analysed together to obtain baseline characteristics of the group 
as well as to determine the prevalence of CFRD.  The data was then divided into 4 
groups for further analysis based on glucose tolerance as normal glucose tolerance, 
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impaired glucose tolerance, CFRD without fasting hyperglycaemia and CFRD with 
fasting hyperglycaemia.  
For subsequent analysis, the patients with CFRD including CFRD without fasting 
hyperglycaemia and CFRD with fasting hyperglycaemia were analysed together.  
Final analysis was performed comparing patients with normal glucose tolerance to 
patients with abnormal glucose homeostasis.  This latter group included patients with 
impaired glucose tolerance, CFRD without fasting hyperglycaemia and CFRD with 
fasting hyperglycaemia.  
 
Prevalence was expressed as a percentage.  
The continuous variables (age, BMI, lung function, creon dosage, duration of 
corticosteroid use, maximal single course of corticosteroid use, HBA1c) were 
expressed as median and range, as all data was non-normally distributed.  Comparison 
between two groups of patients (normal glucose tolerance and abnormal glucose 
homeostasis) was performed using the Mann-Whitney test as data was non-normally 
distributed.  When three groups were compared (normal glucose tolerance, impaired 
glucose tolerance and CFRD) continuous variables were compared using the Kruskal 
Wallis test. 
 
The categorical variables (sex, genotype, creon required and corticosteroid required) 
were expressed as frequency, percentage or proportion.  The two groups of patients 
(normal glucose tolerance and abnormal glucose tolerance) were compared using the 
Fisher exact test. 
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When three groups were compared (normal glucose tolerance, impaired glucose 
tolerance and CFRD) categorical variables were also compared using the Fisher exact 
test.  
Significance was set at a p value of < 0.05. 
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3.0 RESULTS 
 
3.1 Overall results (Table 3.1) 
 
Fifty patient files were reviewed. There were 24 male and 26 female patients. 
The median age of patients attending the clinic was 24.7 years (Range 17.1 – 51.0 
years).   
A total of 32 patients (64%) were homozygous for !"#$%&"'()*)+,-."/0"1*)+2-)3"
(28%) were heterozygous and 4 patients (8%) had two other mutations excluding 
!#$%&4 
On the basis of an oral glucose tolerance test, 12 patients (24%) had normal glucose 
tolerance, 10 (20%) had impaired glucose tolerance, 23 (46%) had CFRD without 
fasting hyperglycaemia and 3 patients (6%) had CFRD with fasting hyperglycaemia. 2 
patients (4%) did not have OGTT done and therefore could not be categorized.  These 
2 patients did not have pancreatic insufficiency (Figure 3.1). 
 
The median BMI was 19.9 kg/m
2
 (Range 15.6 to 28.0 kg/m
2
) which is in the normal 
range for BMI. 
 
Pulmonary function testing revealed a median FEV1 of 2.2 litres per second (Range 
0.6 to 4.0 litres/s) and a median percentage predicted FEV1 of 59.6 % (Range 14.0 to 
106.0 %).  This is lower than the expected 80 % for normal subjects. 
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Figure 3.1: Number of patients within each group based on OGTT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal glucose tolerance 
                   
                     12 
Abnormal glucose homeostasis 
                            
                        36 
Unclassified 
         
          2    
Impaired glucose tolerance 
 
                       10 
CFRD 
 
    26 
CFRD without fasting 
hyperglycaemia 
 
                              23  
CFRD with fasting hyperglycaemia 
 
                          3 
Total patients 
 
          50 
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Forty eight patients (96%) had pancreatic insufficiency and 2 patients (4%) had no 
pancreatic insufficiency.  Of the 48 patients who had pancreatic insufficiency, 46 
required lipase enzyme replacement (96%).  The median amount of Creon required 
per day was 275 000 lipase units (Range 30 000 to 1 000 000 lipase units) 
 
Thirty two patients (64 %) had never required intravenous or oral corticosteroid 
treatment during their time at the clinic (2004 to 2009) and 18 patients (36%) had.  
The median total corticosteroid dose received by these 18 patients during their time in 
the clinic was 607.5 mg (Range 20-1995mg). 
 
The maximum single course dosage of corticosteroids was 385mg (Range 20-700mg).  
The median total duration of corticosteroid usage was 18.5 days (Range: 1- 158 days).  
47 patients had an HBA1c performed with a median of 5.8 % (Range 5.0 to 12.9%) 
 
Two patients did not have OGTT and therefore could not be classified into any of the 
above groups.  These patients did not have pancreatic insufficiency and have never 
required corticosteroids.  These patients were not included in subsequent statistical 
analysis.   
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Table 3.1: Characteristics of the CF population according to OGTT 
 
*Note: All continuous variables are reported as median and range 
 
Key: 
BMI = Body mass index 
HBA1c = Haemoglobin A1c  
FEV1 = Forced expiratory volume in 1 second 
CS = Corticosteroid 
 
 Normal glucose 
tolerance 
 
Impaired 
glucose tolerance 
CFRD without 
fasting 
hyperglycaemia 
CFRD with 
fasting 
hyperglycaemia 
Number 12 10 23 3 
Sex:  [n,(percent)] 
         Male  
         Female 
 
5 (42) 
7 (58) 
 
6 (60) 
4 (40) 
 
11 (48) 
12 (52) 
 
0 (0) 
3 (100) 
Genotype: 
[n,(percent)] 
Homozygous 
Heterozygous 
Other 
 
 
6 (50) 
4 (33) 
2 (17) 
 
 
7 (70) 
3 (30) 
0 (0) 
 
 
14 (61) 
7  (30) 
2  (9) 
 
 
3 (100) 
0 (0) 
0 (0) 
Age (Years)* 26.1(20-37) 23.8(17.5-26.6) 25.8(19.1-51.1) 30.3(21.7-32.1) 
BMI (kg/m
2
)* 20.7(16.5-24.0) 20.1(17.5-27.8) 19.6(15.6-23.8) 23.7(18.3-26.4) 
HBA1c (%)* 5.6 (5.1-6) 5.9 (5-7) 6.0 (5.3-12.6) 8.6 (5.2-12.9) 
FEV1 (litres/s)* 2.4(0.79-4) 2.1(0.77-3.8) 1.6(0.56-3.7) 2.1(1.67-2.8) 
FEV1 percentage 
predicted (%)* 
71.5(26.0-92.0) 52.5(19.0-106.0) 55.0(14.0-93.0) 66.0(58.0-93.0) 
Exocrine 
pancreatic 
insufficiency (n) 
12 10 23 3 
Creon required 
[n, (percent)] 
12 (100) 10 (100) 22 (96) 2 (67) 
Creon dose  
(lipase units)* 
337500 
(30000-1000000) 
175000 
(40000-750000) 
250000 
(30000-625000) 
462500 
(300000-625000) 
Corticosteroid 
treatment  
[n,(percent)] 
2 (17) 3 (33) 11 (48) 2 (67) 
Cumulative CS 
dose (mg)* 
880 (590–1170) 720 (550-1180) 625 (20 – 1995) 342.5 (300 – 385) 
Maximum single 
CS course (mg)* 
420 (420 – 420) 420 (250-420) 350 (20 – 700) 255 (210 – 300) 
Total duration of 
CS use (days)* 
17.5 (13.0 – 22.0) 24.0 (15.0 – 44.0) 22.0 (1.0-158.0) 12.0 (10.0 –14.0) 
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3.2 Results by group 
3.2.1 Normal Glucose tolerance compared to abnormal glucose homeostasis 
(Table 3.2) 
 
Twelve patients had normal glucose tolerance, 36 patients had abnormal glucose 
homeostasis including 10 patients with impaired glucose tolerance and 26 patients 
with CFRD (23 had CFRD without fasting hyperglycaemia and 3 had CFRD with 
fasting hyperglycaemia) 
The continuous variables in each group (age, BMI, FEV1, percentage predicted FEV1, 
creon dose, corticosteroid use, HBA1c) were compared using the Mann Whitney test.  
All continuous variables except HBA1c failed to show any significance with p values 
> 0.05. The HBA1c value was higher in patients with abnormal glucose homeostasis 
compared with values in patients with normal glucose tolerance (p = 0.05)    
 
The categorical variables in each group (genotype, sex, creon required and 
corticosteroid required) were compared using the Fisher Exact test.  There was no 
statistical significance between the variables in the two groups. 
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Table 3.2: Characteristics of patients with normal glucose tolerance vs  abnormal 
glucose homeostasis 
 
 
 
*Note: All continuous variables are reported as median and range 
 
Key: 
BMI = Body mass index 
HBA1c = Haemoglobin A1c  
FEV1 = Forced expiratory volume in 1 second 
CS = Corticosteroid 
 
 
 
 
 
 
 
Normal glucose 
tolerance 
 
(n=12) 
Abnormal glucose 
homeostasis 
 
(n=36) 
p value  
 
Sex: [n,(percent)] 
         Male 
         Female 
 
5 (42) 
7 (58) 
 
17 (47) 
19 (53) 
 
0.74 
Genotype:   
[n,(percent)] 
Homozygous 
Heterozygous 
Other 
 
 
6 (50) 
4 (33) 
2 (17) 
 
 
24 (67) 
10 (28) 
2   (5) 
 
 
0.34 
 
 
Age (Years)* 26.1(20.0-37.0) 24.6(17.5-51.1) 0.51 
BMI (kg/m
2
)* 20.7(16.5-24.0) 19.7(15.6-27.8) 0.68 
HBA1c (%)* 5.6 (5.1-6.0) 5.8(5.0-12.9) 0.05 
FEV1 (litres/s)* 2.4(0.8-4.0) 2.0(0.56-3.8) 0.12 
FEV1 percentage 
predicted (%)* 
71.5(26.0-92.0) 55(14.0-106.0) 0.10 
Creon required 
[n,percent)] 
12 (100) 34 (94) 1.00 
Creon dose  
(lipase units)* 
337500 
(30000-1000000) 
250000 
(30000-750000) 
0.51 
Corticosteroid 
treatment 
([n,(percent)] 
2 (17) 16 (44) 0.17 
 
Cumulative CS 
dose (mg)* 
880 (590–1170) 592.5 (20 – 1995) 0.72 
Maximum single 
CS course (mg)* 
420 (420 – 420) 325 (20 - 700) 0.35 
Total duration of 
CS use (days)* 
17.5 (13.0 – 22.0) 18.5 (1.0 – 158.0) 0.78 
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3.2.2 Impaired glucose tolerance compared to CFRD (Table 3.3) 
 
Twelve patients had normal glucose tolerance, 10 patients had impaired glucose 
tolerance and 26 patients had CFRD (23 had CFRD without fasting hyperglycaemia 
and 3 had CFRD with fasting hyperglycaemia). 
The continuous variables in each group (age, BMI, FEV1, percentage predicted FEV1, 
creon dose, corticosteroid use, HBA1c) were compared using the Kruskal Wallis test 
but failed to show any significance with p values all > 0.05.  The HBA1c comparison 
approached significance though with higher values in patients with impaired glucose 
tolerance and CFRD (p=0.08 and 0.07). 
 
The categorical variables in each group (genotype, sex, creon required and 
corticosteroid required) were compared using the Fisher Exact test.  There was no 
statistical significance between the three groups. 
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Table 3.3: Characteristics of patients with normal glucose tolerance, impaired 
glucose tolerance and CFRD 
 
 
 
*Note: All continuous variables are reported as median and range 
 
Key: 
BMI = Body mass index 
HBA1c = Haemoglobin A1c  
FEV1 = Forced expiratory volume in 1 second 
CS = Corticosteroid 
 
 Normal glucose 
tolerance 
(n=12) 
Impaired 
glucose tolerance 
(n=10) 
CFRD 
 
(n=26)  
p value  
Sex: [n,(percent)] 
         Male 
         Female 
 
5 (42) 
7 (58) 
 
6 (60) 
4 (40) 
 
11 (42) 
15 (58) 
 
0.69 
Genotype:   
[n,(percent)] 
Homozygous 
Heterozygous 
Other 
 
 
6 (50) 
4 (33) 
2 (17) 
 
 
7 (70) 
3 (30) 
0 (0) 
 
 
17 (65) 
7   (27) 
2   (8) 
 
 
0.77 
 
Age (Years)* 26.1(20.0-37.0) 23.8(17.5-26.6) 26.4(19.1-51.1) 0.21 
 
BMI (kg/m
2
)* 20.7(16.5-24.0) 20.1(17.47-27.8) 19.6(15.6-26.4) 0.54 
 
HBA1c (%)* 5.6 (5.1-6.0) 5.9(5.0-7.0) 6.1(5.2-12.9) 0.08 
 
FEV1 (litres/s)* 2.4(0.8-4) 2.1(0.8-3.8) 1.8(0.6-3.7) 0.17 
 
FEV1 percentage 
predicted (%)* 
71.5(26-92) 52.5(19.0-106.0) 56.5(14.0-93.0) 0.24 
 
Creon required 
[n,percent)] 
12 (100) 10 (100) 24 (96) 1.00 
Creon dose  
(lipase units)* 
337500 
(30000-1000000) 
175000 
(40000-750000) 
275000 
(30000-625000) 
 
0.64 
 
Corticosteroid 
treatment 
[n,(percent)] 
2 (17) 3 (33) 13 (50) 0.14 
Cumulative CS 
dose (mg)* 
880 (590–1170) 720 (550-1180) 560 (20 – 1995) 0.81 
 
Maximum single 
CS course (mg)* 
420 (420 – 420) 420 (250-420) 300 (20 – 700) 0.5 
 
Total duration of 
CS use (days)* 
17.5 (13.0 – 22) 24 (15.0 – 44.0) 14.0 (1.0-158.0) 0.65 
 
 25 
 
4.0 DISCUSSION 
The prevalence of CFRD in the population of Cystic fibrosis patients in the Adult 
Cystic Fibrosis Unit, Ward 496, Charlotte Maxeke Johannesburg Academic Hospital 
was 54 % (including all patients with CFRD without fasting hyperglycaemia and 
patients with CFRD with fasting hyperglycaemia).  75 % of patients have abnormal 
glucose homeostasis (This includes patients with impaired glucose tolerance, CFRD 
without fasting hyperglycaemia and CFRD with fasting hyperglycaemia). 
 
The risk for developing CFRD is increased with increasing age, presence of exocrine 
pancreatic insufficiency, lower BMI, !F508 homozygous genotype and female gender 
(Marshall et al. 2005, Bismuth et al. 2008, Blackman et al. 2009, van den Berg, 
Kouwenberg & Heijerman 2009) It is unclear whether the use of corticosteroids is 
associated with an increased incidence of CFRD (Blackman et al. 2009).     
These potential risk factors were analysed in the cohort of patients attending the CF 
clinic at Charlotte Maxeke Johannesburg Academic Hospital.  64 % of patients in the 
clinic are homozygous for the !#$%&"'()*)+,-4""56+3"7+8(92"+3":,;29")6*)")62"<%"="
quoted in the literature (Preumont, Hermans & Buysschaert 2008).  The median age 
of patients attending the clinic was 24.7 years (Range 17.1 – 51.0 years).  There was 
no statistically significant difference in age between the groups of patients.  As the 
cohort of patients increase in age, there may be a difference between patients with and 
patients without CFRD.  The age at onset as well as the prevalence for different age 
groups was not assessed. 
All the patients included in the final analysis (48) had pancreatic insufficiency and 
this was therefore not an independent risk factor for CFRD in this cohort. 
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The median BMI of patients in this cohort was 19.9 kg/m
2 
(Range 15.6 to 28.0 kg/ 
m
2
).  This is within the normal range for BMI and indicates the overall good 
nutritional status of this cohort of patients.  There was no statistically significant 
difference in BMI between the two groups. 
In this cohort, there were 24 males and 26 female patients.  The female gender was 
not associated with a higher incidence of CFRD.   
In keeping with other studies, corticosteroid usage was also not associated with a 
higher incidence of CFRD.  Only a small number of patients (36%) had used 
corticosteroids during their time in the clinic (2004 – 2009) and these corticosteroids 
were prescribed for a short period (Median 18.5 days).   
 
Pulmonary function in terms of FEV1 was also analysed to assess whether patients 
with CFRD had worse pulmonary function when compared to patients without CFRD.    
The patients with CFRD did not demonstrate worse pulmonary function compared to 
patients without CFRD.  This may be as a result of early screening and diagnosis of 
CFRD as well as aggressive treatment protocols followed within the unit in terms of 
limiting invasive respiratory tract infections.   
HBA1C values were compared to ascertain if values were higher in patients with 
CFRD even though HBA1C is not used as part of screening for the disease. HBA1c 
values were higher in patients with abnormal glucose homeostasis compared to 
patients with normal glucose tolerance (p=0.05).  HBA1c is a marker of long term 
glycaemic control.  The median value of 5.8 % in patients with abnormal glucose 
homeostasis is still well below the value of 6.5 % - 7.5% accepted as an indicator of 
tight glycaemic control (National Institute for Health and Clinical Excellence (NICE), 
2008).  This indicates that patients with abnormal glucose homeostasis are being 
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managed effectively and are compliant on treatment and as a result, are achieving 
tight glycaemic control.  This value may also indicate that the patients in this cohort 
are diagnosed early.  The overall value of HBA1c in patients with abnormal glucose 
homeostasis still remains questionable as patients with cystic fibrosis have chronic 
inflammation and the life span of the red blood cells will be shortened resulting in 
lower levels of HBA1c (Lanng et al. 1995). 
 
The cohort of patients at the CF clinic at Charlotte Maxeke Johannesburg Academic 
Hospital only includes about 50 patients and therefore only 50 patient files were 
reviewed.  The data was of a high quality and good records were available on all 
patients.  Two patients however did not have OGTT done and could not be classified 
into any groups and were not included in the comparative analysis.   
The small sample size is a limitation of this study.  On statistical analysis certain 
measures like FEV1 and age may approach significance if larger numbers were 
available.  The patients with impaired glucose tolerance and CFRD (including CFRD 
without fasting hyperglycaemia and CFRD with fasting hyperglycaemia) were 
included together in a group called abnormal glucose homeostasis to increase the 
statistical power.  When compared to data regarding prevalence and risk factors for 
CFRD from CF centres in America and the United Kingdom and Europe this sample 
size is exceedingly small in comparison.  Marshall et al collected data from 8247 CF 
patients in the Intermountain CF centre in Utah (Marshall et al. 2005). 
Adler et al was able to review data from 50 CF clinics in the United Kingdom, which 
included 8029 patients (Adler et al. 2007).  The observed prevalence in this research 
report was in line with the prevalence of CFRD in these large CF centres. 
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The significance of their observations with regard to other risk factors may be more 
significant than the observations in this study based on the larger cohort of patients.   
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5.0 CONCLUSIONS 
Cystic fibrosis is a common autosomal recessive condition.  With improved medical 
care, the survival of patients with CF into adulthood has increased.  This has resulted 
in patients with CF developing complications like cystic fibrosis related diabetes.   
 
A retrospective patient file review was performed on the files in the adult Cystic 
Fibrosis Unit, Ward 496, Charlotte Maxeke Johannesburg Academic Hospital to 
determine the prevalence of CFRD in this population.  The characteristics of these 
patients were also noted and analysed to ascertain if any risk factors could be found 
for the development of CFRD. 
 
The prevalence of CFRD in the population of cystic fibrosis patients in the Adult 
Cystic Fibrosis Unit, Ward 496, Charlotte Maxeke Johannesburg Academic Hospital 
was 54 % (including all patients with CFRD without fasting hyperglycaemia and 
patients with CFRD with fasting hyperglycaemia).  75 % of patients have abnormal 
glucose homeostasis (This includes patients with impaired glucose tolerance, CFRD 
without fasting hyperglycaemia and CFRD with fasting hyperglycaemia).  The above 
figures correlate well with data from other centers in the world.  
 
Possibly related to the small sample size, analyses failed to demonstrate any 
statistically significant difference in the characteristics of patients with and without 
CFRD. The characteristics analysed included, age, sex, genotype, pulmonary 
function, corticosteroid use and HBA1c.  Of note, the HBA1c values were higher in 
patients with abnormal glucose homeostasis compared to patients with normal glucose 
tolerance. 
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This is the first study to look at these factors in the South African CF population and 
only a small cohort of patients has been studied.  In the future, collaboration with 
other cystic fibrosis centres may provide a larger cohort of patients to analyse.  This 
may provide better insight into the prevalence of CFRD in the overall South African 
CF population as well as insight into the risk factors leading to the development of 
CFRD.   
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